{
    "clinical_study": {
        "@rank": "148062", 
        "arm_group": [
            {
                "arm_group_label": "Mild hepatic impairment group", 
                "arm_group_type": "Experimental", 
                "description": "Mild hepatic impairment group by Child-Pugh scores"
            }, 
            {
                "arm_group_label": "Moderate hepatic impairment group", 
                "arm_group_type": "Experimental", 
                "description": "Moderate hepatic impairment group by Child-Pugh scores"
            }, 
            {
                "arm_group_label": "Healthy volunteers", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemigliptin dosing in Healthy subjects"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an\n      additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy\n      White subjects will be investigated."
        }, 
        "brief_title": "Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatic Impairment", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects who are able to understand and follow instructions during\n             the study and available for study participation.\n\n          -  Signed informed consent.\n\n          -  White\n\n        Exclusion Criteria:\n\n          -  Unwilling or unable to give informed consent.\n\n          -  As a result of the medical screening process, a study physician considers the subject\n             unfit for the study.\n\n          -  The subject has a history of drug or other allergy which contraindicated study\n             participation.\n\n          -  Female subjects who are pregnant or lactating.\n\n          -  Any other condition (surgical or medical) or history of severe disease with sequelae\n             which increases the risk to the subject or affected absorption, distribution,\n             metabolism or excretion of the study drug or otherwise"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004587", 
            "org_study_id": "LG-DPCL014"
        }, 
        "intervention": {
            "arm_group_label": [
                "Mild hepatic impairment group", 
                "Moderate hepatic impairment group", 
                "Healthy volunteers"
            ], 
            "description": "Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.", 
            "intervention_name": "Gemigliptin", 
            "intervention_type": "Drug", 
            "other_name": "Zemiglo"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatic impairment", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Gemigliptin"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "larissa.zimmer@crs-group.de", 
                "last_name": "Larissa Zimmer", 
                "phone": "49 431 89998 04"
            }, 
            "facility": {
                "address": {
                    "city": "Kiel", 
                    "country": "Germany", 
                    "state": "Schleswig-Holstein", 
                    "zip": "24105"
                }, 
                "name": "CRS Clinical Research Services"
            }, 
            "investigator": {
                "last_name": "Atef Halabi, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single-center, Open-label Trial, Investigating the Pharmacokinetics, Pharmacodynamics and the Safety Profile After a Single Oral Dose of Gemigliptin (Investigational Product) in Healthy Subjects and Subjects With Mild or Moderate Hepatic Impairment and After Multiple Oral Dose in Healthy Subjects", 
        "overall_contact": {
            "email": "sikim@lgls.com", 
            "last_name": "Sung Il Kim", 
            "phone": "82 2 6924 3112"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood samples will be prepared at planed points.", 
            "measure": "AUC", 
            "safety_issue": "No", 
            "time_frame": "Several time points until 72hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}